

Discordance between amyloid- β PET and CSF biomarkers : clinical and pathophysiological consequences = Amüloid- β staatuse vastuolu PET-uuringul ning liikvorianalüüsil : kliiniline ja patofüsioloogiline tähendus

Reimand, Juhan 2021 <https://doi.org/10.23658/taltech.15/2021> https://www.eester.ee/record=b5431268*est
<https://digikogu.taltech.ee/et/Item/d14a365f-fbfc-4595-923e-473262485fe2>

Discordant amyloid- β PET and CSF biomarkers and its clinical consequences

Wilde, Arno de; **Reimand, Juhan**; Teunissen, Charlotte E.; Zwan, Marissa Alzheimer's Research & Therapy 2019 / art. 78, 13 p. : ill
<https://doi.org/10.1186/s13195-019-0532-x> [Journal metrics at Scopus](#) [Article at Scopus](#) [Journal metrics at WOS](#) [Article at WOS](#)

Why is amyloid- β PET requested after performing CSF biomarkers?

Reimand, Juhan; Groot, Colin; Teunissen, Charlotte E.; Windhorst, Albert D.; Boellaard, Ronald; Barkhof, Frederike; Nazarenko, Sergei; van der Flier, Wiesje M.; Scheltens, Philip; Ossenkoppele, Rik; Bouwman, Femke Journal of Alzheimer's disease 2020 / p. 559-569 <https://doi.org/10.3233/JAD-190836> [Journal metrics at Scopus](#) [Article at Scopus](#) [Journal metrics at WOS](#) [Article at WOS](#)